SEC Filing Summary: BioSig Technologies, Inc. (BSGM)
Business Context and Reporting Period
This Form 8-K Current Report was filed by BioSig Technologies, Inc. on July 31, 2023. The filing discloses the entry into a material definitive agreement and the unregistered sale of equity securities. The company is incorporated in Delaware and trades on the NASDAQ Capital Market under the symbol BSGM.
Key Financial Metrics and Transaction Details
The filing details a private placement transaction (the "July PIPE") rather than standard periodic financial results. Key metrics from the transaction include:
- Total Consideration Raised: $1,499,999.79
- Common Stock Sold: 1,467,624 shares at $1.02206 per share
- Warrants Issued to Investor: Warrant to purchase 733,812 shares at an exercise price of $0.95956 per share
- Warrant Terms: Exercisable six months after issuance; expires five and one-half years after issuance
- Advisor Compensation: A warrant to purchase 110,072 shares issued to Laidlaw & Company (UK) Ltd. at an exercise price of $0.95956 per share
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity positions as this is a current report focused on a specific transaction.
Material Changes
The primary material change is the increase in outstanding equity and potential dilution resulting from the issuance of 1,467,624 shares of common stock and warrants covering 843,884 shares (733,812 to the investor and 110,072 to the financial advisor). The transaction was executed under Section 4(a)(2) and Regulation D exemptions from registration.
Outlook, Risks, and Management Commentary
Management commentary is limited to the execution of the Securities Purchase Agreement and the Engagement Agreement with Laidlaw & Company. The filing does not contain forward-looking guidance, risk factors, or discussion of contingencies beyond the standard representations and warranties typical for such transactions. The company engaged Laidlaw as a financial advisor and introducing broker for this offering.
Investor Verification Checklist
- Verify the exact number of shares outstanding post-transaction to assess dilution impact.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and restrictions.
- Confirm the vesting schedule and exercise conditions for the warrants issued to the investor and Laidlaw.
- Check subsequent filings for the use of proceeds from the $1.5 million raised.